CeQur Medical Director and consultant for diabetes drug development. He trained in Internal Medicine and Diabetology at the Universities Goettingen and Marburg, Germany, and Geneva, Switzerland. In 1993, he joined Lilly Germany as Clinical Research Physician for Diabetes where he was responsible for the clinical development of insulin lispro (Humalog). From 1996 to 1998 Dr. Trautmann was a Global Physician in the Endocrine Therapeutic Area with responsibilities for early phase development of novel therapeutic approaches in the areas of obesity and type 2 diabetes treatments. Thereafter he moved to the Lilly Research Laboratories in Hamburg and coordinated early phase clinical programs. He worked on several programs in the areas of insulin, insulin delivery, and GLP-1. Under his leadership exenatide (Byetta and Bydureon) was approved as treatment for Diabetes in Europe, the USA, and Japan. Dr Trautmann is a member of several national and international associations for Diabetes and Endocrine Research and has authored numerous publications in this field.

 diabetes drug development  Internal Medicine